April 19, 2017
Forward Pharma reports $33M net loss
Forward Pharma has reported financial results for the year ended December 31, 2016.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 19, 2017
Faron Pharmaceuticals wants to see new names in its board
Faron Pharmaceuticals has decided to add new names to its board, for which the shareholders will decided in May.
April 18, 2017
Faron to test its immuno switch antibody with the University of Birmingham Medical School
Faron Pharmaceuticals and the University of Birmingham Medical School, have signed an agreement to begin a liver cancer program for clinical testing of Faron’s immuno switch antibody Clevegen.
April 18, 2017
Circassia’s house dust mite allergy test gives unexpected result
Circassia Pharmaceuticals’s study of house dust mite allergy immunotherapy phase IIb field study failed to meed its primary endpoint, the company said Tuesday.
April 18, 2017
FDA grants breakthrough therapy designation to Novartis’s B-cell cancer
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’s CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies.
April 18, 2017
FDA nods for Verona’s inhibitor trial
Respiratory diseases biopharmaceutical specialist, Verona Pharma said Tuesday that the U.S. Food and Drug Administration has given the green light for the kick-start of a pharmacokinetic (PK) clinical trial in the U.S. for its RPL554 candidate, with the acceptance of an Investigational New Drug application (IND).
April 18, 2017
Two European pharmaceutical giants unite to fight certain type of liver disease
Novartis and Allergan have joined forces to conduct a Phase IIb study to test combination of a Novartis FXR agonist and Allergan’s cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH).
April 18, 2017
GeNeuro starts Phase 2a study with GNbAC1 in type 1 diabetes in Australia
GeNeuro, a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, has initiated a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes (T1D).
April 18, 2017
DermTech partners with two pharmaceutical companies
DermTech, Inc., a player in non-invasive molecular dermatology, has entered into two collaborations with multi-national pharmaceutical companies,
April 17, 2017
OncoMed’s lung cancer drug fails mid-stage study, shares tumble
OncoMed Pharmaceuticals Inc said on Monday its experimental lung cancer drug failed a mid-stage study, sending its shares tumbling 30 percent in premarket trading.